The oncofetal protein IMP3: A novel molecular marker to predict aggressive meningioma

Archives of Pathology and Laboratory Medicine

Volumn 135, Issue 8, 2011, Pages 1032-1036

  Hao, Suyang ^a   Smith, Thomas W ^a   Chu, Peigou G ^c   Liu , Qin ^b   Ok, Chi Young ^a   Woda, Bruce A ^a   Lu, Di ^a   Lin, Pei ^d   Wang, Sa A ^d   Dresser, Karen ^a   Rock, Kenneth L ^a   Jiang, Zhong ^a  

^a UMASS MEMORIAL MEDICAL CENTER   (United States)

^b UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

^c CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

^d UNIVERSITY OF TEXAS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

IMP3 PROTEIN, HUMAN; RNA BINDING PROTEIN; TUMOR MARKER;

ARTICLE; CANCER INVASION; CLINICAL TRIAL; FEMALE; HUMAN; KAPLAN MEIER METHOD; MALE; MENINGIOMA; METABOLISM; MIDDLE AGED; MORTALITY; MULTICENTER STUDY; PROGNOSIS; SURVIVAL RATE; TUMOR RECURRENCE; UNITED STATES;

CALIFORNIA; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MASSACHUSETTS; MENINGEAL NEOPLASMS; MENINGIOMA; MIDDLE AGED; NEOPLASM INVASIVENESS; NEOPLASM RECURRENCE, LOCAL; PROGNOSIS; RNA-BINDING PROTEINS; SURVIVAL RATE; TUMOR MARKERS, BIOLOGICAL;

EID: 80051969140     PISSN: 00039985     EISSN: 15432165     Source Type: Journal    
DOI: 10.5858/2009-0652-OAR2     Document Type: Article

References (35)

1. Perry A, Louis DN, Scheithauer B, Budka H, Von Deimling A. Meningiomas. In: Louis DN, Ogaki H, Wiestler OD, Cavanee WK, eds. Pathology and Genetics of Tumours of the Central Nervous System. Lyon, France: IARC Press; 2007:164-172. World Health Organization Classification of Tumours; vol 1.
2. de la Monte SM, Flickinger J, Linggood RM. Histopathologic features predicting recurrence of meningiomas following subtotal resection. Am J Surg Pathol. 1986;10(12):836-843. (Pubitemid 17197757)
3. Jaaskelainen J, Haltia M, Laasonen E, Wahlstrom T, Valtonen S. The growth rate of intracranial meningiomas and its relation to histology: an analysis of 43 patients. Surg Neurol. 1985;24(2):165-172. (Pubitemid 15072926)
4. Jellinger K, Slowik F. Histological subtypes and prognostic problems in meningiomas. J Neurol. 1975;208(4):279-298.
5. Maier H, Ofner D, Hittmair A, Kitz K, Budka H. Classic, atypical, and anaplastic meningioma: three histopathological subtypes of clinical relevance. J Neurosurg. 1992;77(4):616-623.
6. Perry A, Scheithauer BW, Stafford SL, Lohse CM, Wollan PC. "Malignancy"in meningiomas: a clinicopathologic study of 116 patients, with grading implications. Cancer. 1999;85(9):2046-2056. (Pubitemid 29202781)
7. Perry A, Stafford SL, Scheithauer BW, et al. Meningioma grading: an analysis of histologic parameters. Am J Surg Pathol. 1997;21 (12):1455-1465. (Pubitemid 27528256)
8. Abramovich CM, Prayson RA, Abramovich CM, Prayson RA. MIB-1 labeling indices in benign, aggressive, and malignant meningiomas: a study of 90 tumors. Hum Pathol. 1998;29(12):1420-1427. (Pubitemid 28563974)
9. Amatya VJ, Takeshima Y, Sugiyama K, et al. Immunohistochemical study of Ki-67 (MIB-1), p53 protein, p21WAF1, and p27KIP1 expression in benign, atypical, and anaplastic meningiomas. Hum Pathol. 2001;32(9):970-975. (Pubitemid 32911320)
10. Barresi V, Cerasoli S, Vitarelli E, et al. Density of microvessels positive for CD105 (endoglin) is related to prognosis in meningiomas. Acta Neuropathol. 2O07;114(2):147-156. (Pubitemid 47103525)
11. Bruna J, Brell M, Ferrer I, et al. Ki-67 proliferative index predicts clinical outcome in patients with atypical or anaplastic meningioma. Neuropathology. 2007;2 7(2): 114-120. (Pubitemid 46558206)
12. Bruner JM. Tumors of the meninges and the related tissues. Russell and Rubinstein's pathology of tumors of the nervous system. 6th ed. London, United Kingdom: Arnold; 1998:67-139.
13. Chen HJ, Liang CL, Lu K, et al. Implication of telomerase activity and alternations of telomere length in the histologic characteristics of intracranial meningiomas. Cancer. 2000;89(10):2092-2098.
14. Going JJ. Efficiently estimated histologic cell counts. Hum Pathol. 1994; 25(4):333-336. (Pubitemid 24151116)
15. Hancq S, Salmon I, Brotchi J, et al. Detection of S100B, S100A6 and galectin-3 ligands in meningiomas as markers of aggressiveness. Int J Oncol. 2004;25(5):1233-1240.
16. Kim YJ, Ketter R, Henn W, et al. Histopathologic indicators of recurrence in meningiomas: correlation with clinical and genetic parameters. Virchows Arch. 2006;449(5):529-538. (Pubitemid 44722321)
17. Kim YJ, Ketter R, Steudel Wl, et al. Prognostic significance of the mitotic index using the mitosis marker anti-phosphohistone H3 in meningiomas. Am J Clin Pathol. 2007;128(1):118-125. (Pubitemid 47121724)
18. Maes L, Lippens E, Kalala JP, et al. The hTERT-protein and Ki-67 labelling index in recurrent and non-recurrent meningiomas. Cell Prolif. 2005;38(1):3-12. (Pubitemid 40229263)
19. Maillo A, Diaz P, Sayagues JM, et al. Gains of chromosome 22 by fluorescence in situ hybridization in the context of an hyperdiploid karyotype are associated with aggressive clinical features in meningioma patients. Cancer. 2001;92(2):377-385. (Pubitemid 32664445)
20. Ribalta T, McCutcheon IE, Aldape KD, et al. The mitosis-specific antibody anti-phosphohistone-H3 (PHH3) facilitates rapid reliable grading of meningiomas according to WHO 2000 criteria. Am J Surg Pathol. 2004,28(11):1532-1536. (Pubitemid 39425522)
21. Roser F, Nakamura M, Ritz R, et al. Proliferation and progesterone receptor status in benign meningiomas are not age dependent. Cancer. 2005; 104(3):598-601. (Pubitemid 41022818)
22. Rushing EJ, Olsen C, Mena H, et al. Central nervous system meningiomas in the first two decades of life: a clinicopathological analysis of 87 patients. J Neurosurg. 2005;103(6)(suppl):489-495. (Pubitemid 44954869)
23. Yamasaki F, Yoshioka H, Hama S, et al. Recurrence of meningiomas. Cancer. 2000;89(5):1102-1110.
24. Jiang Z, Chu PG, Woda BA, et al. Combination of quantitative IMP3 and tumor stage: a new system to predict metastasis for patients with localized renal cell carcinomas. Clin Cancer Res. 2O08;14(17):5579-5584.
25. Jiang Z, Chu PG, Woda BA, et al. Analysis of RNA-binding protein IMP3 to predict metastasis and prognosis of renal-cell carcinoma: a retrospective study. Lancet Oncol. 2006;7(7):556-564. (Pubitemid 43923666)
26. Jiang Z, Lohse CM, Chu PG, et al. Oncofetal protein IMP3: a novel molecular marker that predicts metastasis of papillary and chromophobe renal cell carcinomas. Cancer. 2008;112(12):2676-2682. (Pubitemid 351969211)
27. Sitnikova L, Mendese G, Liu Q, et al. IMP3 predicts aggressive superficial urothelial carcinoma of the bladder. Clin Cancer Res. 2008; 14(6): 1701-1706. (Pubitemid 351469454)
28. Nielsen J, Christiansen J, Lykke-Andersen J, et al. A family of insulin-like growth factor II mRNA-binding proteins represses translation in late development. Mol Cell Biol. 1999;19(2):1262-1270. (Pubitemid 29046868)
29. Mueller-Pillasch F, Pohl B, Wilda M, et al. Expression of the highly conserved RNA binding protein KOC in embryogenesis. Mech Dev. 1999;88(1):95-99. (Pubitemid 29467415)
30. Monk D, Bentley L, Beechey C, et al. Characterisation of the growth regulating gene IMP3, a candidate for Silver-Russell syndrome. J Med Genet. 2002;39(8):575-581. (Pubitemid 34864561)
31. Mueller-Pillasch F, Lacher U, Wallrapp C, et al. Cloning of a gene highly overexpressed in cancer coding for a novel KH-domain containing protein. Oncogene. 1997;14(22):2729-2733. (Pubitemid 27283112)
32. Wang T, Fan L, Watanabe Y, et al. L523S, an RNA-binding protein as a potential therapeutic target for lung cancer. Br J Cancer. 2003;88:887-894. (Pubitemid 36520876)
33. Yantiss RK, Woda BA, Fanger GR, et al. KOC (K homology domain containing protein overexpressed in cancer): a novel molecular marker that distinguishes between benign and malignant lesions of the pancreas. Am J Surg Pathol. 2005;29(2):188-195. (Pubitemid 40170636)
34. Liao B, Hu Y, Herrick DJ, et al. The RNA-binding protein IMP-3 is a translational activator of insulin-like growth factor II leader-3 mRNA during proliferation of human K562 leukemia cells.; Biol Chem. 2005,280(18):18517- 18524. (Pubitemid 41389102)
35. Yaniv K, Fainsod A, Kalcheim C, et al. The RNA-binding protein Vgl RBP is required for cell migration during early neural development. Development. 2003,130(23):5649-5661. (Pubitemid 37540841)